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Summary
Chromosomal instability in human breast cancer is known to take place before mammary neoplasias display morphologi-
cal signs of invasion. We describe here the unexpected finding of a tumor cell population with normal karyotypes isolated
from bone marrow of breast cancer patients. By analyzing the same single cells for chromosomal aberrations, subchromo-
somal allelic losses, and gene amplifications, we confirmed their malignant origin and delineated the sequence of genomic
events during breast cancer progression. On this trajectory of genomic progression, we identified a subpopulation of
patients with very early HER2 amplification. Because early changes have the highest probability of being shared by geneti-
cally unstable tumor cells, the genetic characterization of disseminated tumor cells provides a novel rationale for selecting
patients for targeted therapies.S I G N I F I C A N C E
The hallmark of cancer is genetic instability, which results in a constant clonal divergence of the tumor cell population and gives
rise to therapy-resistant, variant cells. Because only the early changes will be shared among all tumor cells, knowledge about
initiating events may be key to successful treatment. To date, early aberrations have been identified by analysis of morphologically
defined lesions at the primary site. Our finding of disseminated breast cancer cells in bone marrow that show less progressed
genomic changes than preinvasive primary lesions provides a mechanism to uncover cancer-initiating and -promoting genetic or
epigenetic alterations.Introduction
Currently, many cancers can only be cured by timely surgery,
whereas systemic therapies often fail. The major cause for the
poor results of systemic therapies can be traced to the inherent
genetic instability (Loeb, 2001) that constantly generates ther-
apy-resistant, variant cells. While advances in molecular cell
biology may translate into improved treatment, few therapeutic
concepts today address the enormous cellular heterogeneity of
systemic cancer. Importantly, it has recently been shown that
therapeutic responses require first, the widespread presence
of the target (e.g., protein tyrosine kinases such as EGFR or
HER2) and second, the cellular dependence on the target,
which often results from its genetic change (Arteaga and Ba-
selga, 2004; Lynch et al., 2004; Paez et al., 2004; Sordella et
al., 2004). According to these findings, the development of effi-
cient adjuvant systemic therapies should be based on detailed
knowledge about aberrations that are shared among and
essential for tumor cells that disseminate before surgery and
later give rise to lethal metastasis.
Representatives of this highly relevant cell population can be
detected in bone marrow as single cytokeratin-positive cellsCANCER CELL : SEPTEMBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIElong before clinical metastases manifest themselves. In ap-
proximately one-third of cancer patients who are clinically free
of metastasis, 1–2 cytokeratin-positive cells are detected
among 2 × 106 bone marrow cells, while approximately 2% of
samples from patients without known carcinoma are cytokera-
tin positive (Braun et al., 2000b; Klein, 2003). Despite this rare-
ness, cytokeratin-positive tumor cells present in bone marrow
represent an important risk factor for reduced disease-free and
overall survival for many carcinoma patients without overt me-
tastases (Klein, 2003). In particular, an increasing number of
clinical studies on breast cancer confirm the prognostic impact
of these cells for overall survival, disease-free survival, and
skeletal metastasis (Braun et al., 2000b; Gebauer et al., 2001;
Gerber et al., 2001; Wiedswang et al., 2003). In addition, their
detection after adjuvant therapy has been interpreted as a sur-
rogate marker for treatment failure (Braun et al., 2000a), and
their persistence in bone marrow after surgery and adjuvant
therapy has been associated with particularly poor prognosis
(Janni et al., 2005). Together, the clinical data suggest that cy-
tokeratin-positive cells in bone marrow of breast cancer pa-
tients represent important cellular targets for adjuvant ther-
apies.R INC. DOI 10.1016/j.ccr.2005.08.003 227
A R T I C L EUnfortunately, knowledge about the molecular characteris-
tics of cytokeratin-positive cells has remained elusive. Due to
their extreme rareness, double labeling has been the preferred
way to characterize these cells for many years. A novel amplifi-
cation technique (Klein et al., 1999) has then enabled single-
cell genomic analysis and uncovered that cytokeratin-positive
cells of an individual patient are genetically extremely hetero-
geneous before metastasis is clinically detected (Klein et al.,
2002). Moreover, disseminated breast cancer cells often dis-
play chromosomal abnormalities very different from their matched
primary tumors (Schmidt-Kittler et al., 2003). The latter sug-
gests that primary tumors and cell lines derived thereof may
not be the most optimal surrogate tissues to detect therapy
targets present on disseminated cancer cells.
On the other hand, the chromosomal heterogeneity among
disseminated cancer cells of an individual patient before and
the clonal expansion after manifestation of metastases suggest
that chromosomal aberrations may be important for the out-
growth of disseminated cells, while they are not necessary for
systemic spread. The outgrowth of cells that have homed to
different tissues may occur at different rates and result in dif-
ferent genomic rearrangements. In contrast, all disseminated
tumor cells should share the genetic changes that either
caused dissemination or initiated cancer. Identification of such
changes could then be very helpful for the prevention of met-
achronous metastases. The search for tumor-initiating changes
is usually performed using samples of small tumors or morpho-
logically defined preinvasive stages of neoplastic development.
However, it has been found that chromosomal imbalances are
among the earliest changes of morphologically defined lesions
and are associated with hyperproliferation in breast cancer
(Allred et al., 2001; Aubele et al., 2000; Buerger et al., 1999;
Waldman et al., 2000). In particular, chromosomal instability
was shown to occur during the transition from ductal hyperpla-
sia to in situ carcinoma, i.e., before the cancer becomes mor-
phologically invasive (Chin et al., 2004). We recently found that
57% of cytokeratin-positive cells isolated from the bone mar-
row of breast cancer patients without clinically evident metas-
tasis do not display chromosomal aberrations, whereas the
matched primary tumors of the patients regularly harbored
multiple chromosomal alterations (Schmidt-Kittler et al., 2003).
Thus, we reasoned that karyotypically normal (as defined by
comparative genomic hybridization [CGH; Kallioniemi et al.,
1992]) cytokeratin-positive cells in bone marrow may represent
genetically very early stages of breast cancer development—if
they are indeed tumor cells. Their analysis may provide infor-
mation about genetic events that occur before breast neopla-
sias become morphologically detectable and chromosomally
unstable.
Results
Detection of allelic losses in single cells
Cytokeratin-positive cells with normal karyotypes in bone mar-
row could either be nonmalignant cells that are stained for un-
known reasons (e.g., false positive normal bone marrow cells
[Borgen et al., 1998]) or tumor cells that have genetic changes
below the resolution of comparative genomic hybridization
(10–20 Mb). To differentiate between the two possibilities, we
evaluated whether cytokeratin-positive cells display DNA dam-
age when analyzed with higher resolution. Therefore, we tested228whether DNA from single normal cells that had been globally
amplified by adaptor-linker PCR (Klein et al., 1999) is suited for
loss of heterozygosity (LOH) analysis. Because of the possi-
bility that some DNA fragments fail to be amplified in the initial
whole-genome amplification and thus cannot be detected in
subsequent sequence-specific PCR, amplification of single-
copy sequences in a single-cell genome had to be carefully
controlled.
Single control cells were isolated from two groups of donors
(Table S1 in the Supplemental Data available with this article
online). Twenty-one single blood cells were isolated from four
healthy donors after staining with an antibody against mes-
enchymal vimentin (control group 1) and 52 single cytokeratin-
negative cells from bone marrow of patients with malignant ep-
ithelial cancer (control group 2). For the cytokeratin-positive
cells (see below) and control cells, we performed single-cell
CGH to assess the quality of the global amplification and in-
cluded only those cells that could be successfully hybridized
to metaphase chromosomes. All control cells displayed normal
CGH profiles. Control group 1 cells served to uncover a poten-
tially negative influence of the precipitated color substrate or
the antibody binding on the PCR result of cytokeratin-positive
cells. Cells from control group 2 had been incubated with the
same substrate solution during immunocytochemistry and had
not bound the cytokeratin antibody but were isolated from car-
cinoma patients. These patients suffered from breast, prostate,
or various gastrointestinal cancers in clinical stage M0 and
were similar in age to the breast cancer patients from whom
the cytokeratin-positive cells were isolated. All 73 cells were
analyzed for 29 polymorphic markers (see below), and the loss
of PCR bands was assessed. As expected, loss of PCR bands
was occasionally observed in cells from perfectly healthy in-
dividuals (Figure 1B), indicating either random DNA damage in
individual cells or—more likely—random PCR failure. Rarely,
we observed loss of both PCR bands of a specific marker,
which could indicate homozygous loss of a marker, loss of the
remaining allele by PCR failure in a region with true LOH, or
complete PCR failure. Due to this uncertainty, we excluded ho-
mozygous losses for the assessment of LOH. To our surprise,
we found that cells from control group 1 displayed significantly
fewer allelic losses than control group 2 (2.9% [95% confi-
dence interval (CI), 0.1%–5.7%] versus 9.8% [95% CI, 6.8%–
12.8%]; p = 0.006, exact Wilcoxon rank test; Figures 1A–1C),
excluding a negative influence of precipitated color or bound
antibody on the PCR result. The two groups did not differ with
regard to homozygous losses (p = 0.2). Since both groups con-
sisted of randomly picked hematopoietic cells with a diploid
genome, the major differences lay in the younger age of the
donors from group 1 (median age 28 years versus 59 years in
control group 2) and the fact that control group 2 consisted of
patients with cancer. Comparing each marker separately, we
found no significant differences for any marker between control
group 1 and control group 2 (Table 1), suggesting random DNA
loss throughout the genome. The control experiments demon-
strated that LOH analysis with single cells is feasible but re-
quires statistical analysis due to random PCR failure or—possi-
bly—age-dependent DNA loss. For statistical comparison with
cytokeratin-positive cells, we therefore used only the samples
from the age-matched control group 2.CANCER CELL : SEPTEMBER 2005
A R T I C L EFigure 1. Cumulative analysis of allelic loss and microsatellite analysis of
D16S485
A: Allelic loss per cell of all tested markers evaluated for control groups 1
and 2 and cytokeratin-positive cells from groups A–C (groups A and B were
from M0 stage patients, group C was from M1 stage patients, and groups
B and C were from patients with aberrant CGH profiles). Blue dots indicate
heterozygous loss, and red dots indicate homozygous deletions. Error bars
represent 95% confidence interval.
B–D: Polyacrylamide gel run of PCR products (D16S485) generated from
single cells of control group 1 (median age 28 yrs) (B) and control group 2
(median age 58 yrs; C), and cells from patient group A (D). Arrows indicate
loss of one band and asterisks indicate loss of two bands for a particular
cell.LOH analysis of single cytokeratin-positive
cells from bone marrow
To investigate the genome of cytokeratin-positive tumor cells
that were isolated from the bone marrow of breast cancer pa-CANCER CELL : SEPTEMBER 2005tients at higher resolution, we used 27 microsatellite and 2
PCR-RFLP (restriction fragment length polymorphism) mark-
ers. These markers were located on four chromosomes, span-
ning regions from 16 to 44 Mb, around genes whose products
regulate cell adhesion, E-cadherin (CDH1), α-catenin (CTNNA1),
β-catenin (CTNNB1), plakoglobin (JUP), and APC protein (APC)
(Table 1). From 189 single cytokeratin-positive cells that had
been isolated from the bone marrow of 371 breast cancer pa-
tients and studied by CGH (Schmidt-Kittler et al., 2003), we
selected a total of 97 cells from 47 patients for LOH analysis,
which included all cytokeratin-positive cells that displayed nor-
mal CGH profiles and randomly selected cells with chromo-
somal aberrations from patients with metastasis (clinical stage
M1) and without metastasis (clinical stage M0) (Table S1). We
separated these samples into three groups. Cells of groups A
(n = 37) and B (n = 15) were isolated from M0 breast cancer
patients that had normal and abnormal CGH profiles, respec-
tively. Group C (n = 45) cells were isolated from M1 breast can-
cer patients, all of which had abnormal CGH profiles, and
served to uncover genomic changes associated with ad-
vanced disease.
On average, cells from groups A, B, and C displayed 37.3%
(95% CI, 32.8%–41.8%), 48.7% (95% CI, 36.5%–60.8%), and
48.2% (95% CI, 41.7%–54.8%) loss of informative markers,
respectively. For statistical comparison of DNA losses, we used
only the control cells from the age-matched group (control
group 2; Figures 1A–1D). Strikingly, all three groups showed a
significantly (p < 0.001) higher percentage of LOH than control
group 2 cells when evaluated by exact Wilcoxon rank test (Fig-
ure 1A). Cytokeratin-positive cells that harbored chromosomal
abnormalities (groups B and C) displayed a slightly higher rate
of DNA loss than cytokeratin-positive cells with normal karyo-
types, most likely reflecting that some markers map to regions
that are frequently involved in large chromosomal rearrange-
ments. Cells from group A and B suffered more frequently from
homozygous losses than control cells (p = 0.02 and 0.006, re-
spectively), while this was not the case for cells from group C
(p = 0.09). A possible explanation for this finding could be that
a complete PCR failure of a marker is more likely if one allele
has been lost during tumor progression. The reduced incidence
of homozygous losses in cells from group C may therefore indi-
cate a hyperploid genome, since cytokeratin-positive cells
from metastatic patients are often larger than cytokeratin-posi-
tive cells from patients without manifest metastasis (Figures
2A–2D). The significantly higher number of LOH in cytokeratin-
positive cells without chromosomal imbalances (group A) com-
pared to age-matched, bone marrow-derived cytokeratin-
negative cells suggests that cytokeratin antibodies identify a
subpopulation within the bone marrow that displays significant
genetic instability.
Apoptosis does not account for frequent LOH in single
cytokeratin-positive cells
Although the isolated cytokeratin-positive cells looked per-
fectly intact (Figures 2A–2D), we tested whether the high fre-
quency of LOH might result from apoptosis induced in ectopi-
cally homing epithelial cells. We cultured normal mammary
epithelial cells from a sample obtained after breast reduction
surgery (undertaken for a nonneoplastic condition) and se-
lected epithelial cells by generation of mammospheres, which
allow the propagation of mammary precursor cells (Dontu et229
A R T I C L ETable 1. LOH analysis of cytokeratin-positive cells versus age-matched control cells
Marker and genesa Localization (bp)a p value*
Control group 2 Control group 2 Control group 2 Control group 2
versus control group 1 versus group A versus group B versus group C
Chromosome 3 D3S3518 33662359 1.0 0.007** 0.166 0.153
β-catenin markerb 41231926 1.0 0.0003** 0.088 0.023**
(intron 7)
D3S3624 44588821 1.0 0.049** 1.0 <0.0001**
D3S32 46515925 1.0 0.129 1.0 0.0005**
D3S1514 58193152 1.0 0.343 0.169 0.016**
Chromosome 5 D5S299 101675106 1.0 1.0 1.0 0.0003**
rs42427 (intragenic of 112204224 1.0 0.048** 0.025** 0.007**
APC)
D5S346 112241523 1.0 0.132 0.010** 0.001**
D5S471 119076934 1.0 0.088 0.329 0.034**
D5S592 119129568 1.0 0.369 0.298 0.328
D5S615 125191192 1.0 0.129 0.276 0.101
D5S2117 133065027 1.0 0.228 0.088 0.088
D5S816 135329409 1.0 0.066 0.329 0.009**
D5S399 135991437 1.0 1.0 1.0 1.0
D5S500 137874849 1.0 0.088 0.568 0.011**
D5S1360 144877829 1.0 0.129 0.025** 0.427
Chromosome 16 D16S3019 64686681 1.0 0.696 1.0 0.009**
D16S3095 68503731 1.0 0.215 0.01** 0.0008**
D16S485 70292497 1.0 0.008** 0.052 0.0009**
D16S3066 71887336 1.0 0.049** 0.025** <0.0001**
D16S3138 76161268 1.0 0.088 0.039** 0.0005**
D16S3040 78209120 1.0 0.132 0.003** 0.0008**
D16S511 80258795 1.0 0.129 0.023** <0.0001**
Chromosome 17 D17S800 36309949 1.0 0.257 0.657 0.028**
D17S855 (BRCA1 38458270 1.0 0.370 0.298 0.199
intron 20)
D17S1322 (BRCA1 38468875 1.0 0.654 1.0 0.046**
intron 19)
D17S1868 44539852 1.0 0.049** 0.011** 0.0008**
D17S943 45195357 1.0 0.055 0.040** 0.091
D17S1161 53686418 1.0 0.129 0.123 0.013**
*p values of Fisher’s exact test between control group 2 cells and control group 1, group A, group B, or group C cells for each marker corrected for multiple testing by
controlling the FDR. **Significant values.
aMarkers are ordered according to their chromosomal localization in bp (ensembl database [July 2005]; www.ensembl.org).
b Intragenic polymorphism obtained as personal communication from F. van Roy; see also Nollet et al. (1996).al., 2003). Subsequently, the cells were kept under differentiat-
ing conditions. We induced apoptosis by either camptothecin
(Morris and Geller, 1996; incubated 1.5 and 3 hr) or serum star-
vation for 24 hr. Apoptosis was monitored by double staining
using a GFP-annexin V fusion protein and propidium iodide (PI;
Egger et al., 2003). GFP-annexin V single-positive cells (Figures
2E and 2F) were considered to undergo early, double-positive
cells (Figures 2G–2I) to undergo advanced apoptosis. From the
three conditions (1.5 hr camptothecin, 3 hr camptothecin, and
serum starvation), we isolated individual unstained cells, GFP-
annexin V single-positive, and GFP-annexin V-PI double-posi-
tive cells (each n = 10; Figures 2E–2L). Unstained cells were
regarded as nonapoptotic and served as control. After global
amplification, we performed LOH analysis using all markers
(n = 16) for which the donor DNA was informative (Figure S1).
Unlike with the cytokeratin-positive cells from bone marrow,
we did not perform CGH analysis as quality control but in-
cluded cells that were positive in a gene-specific PCR using
primers binding to the cytokeratin 19 sequence.
Compared with unstained control cells, GFP-annexin V sin-
gle-positive and GFP-annexin V-PI double-positive cells
showed a nonsignificant increase of LOH (p = 0.4; Figure 2M230and Figure S1). The frequency of LOH did not differ between
the groups for any marker when analyzed individually. Markers
displaying complete PCR failure were excluded. However, in
contrast to the cytokeratin-positive and control group 2 cells,
where homozygous losses occurred randomly, complete PCR
failure occurred in four cells that showed “homozygous dele-
tion” of 88%–100% of markers. Since such DNA samples are
unsuited for CGH, they would not have been included in our
study of cytokeratin-positive cells. Of note, the almost com-
plete loss of DNA occurred exclusively in camptothecin-
induced apoptosis. We therefore compared the different
modes of apoptosis induction for their effect on the rate of
LOH. Interestingly, LOH slightly increased with exposure to
camptothecin, while apoptotic serum-starved cells did not
show an increase of LOH as compared to the unstained con-
trols (Figure 2N). Comparing all GFP-annexin V single-positive
and GFP-annexin V-PI double-positive cells (n = 16, excluding
the four cells with 88%–100% loss of DNA) with the cytokera-
tin-positive cells from group A, the latter displayed significantly
higher frequency of LOH than apoptotic cells (p < 0.001).
We then tested two cancer cell lines (the breast cancer cell
line SKBR3 and the colon carcinoma cell line SW480) and iso-CANCER CELL : SEPTEMBER 2005
A R T I C L EFigure 2. Apoptosis does not account for frequent LOH in cytokeratin-positive cells
A–D: Single cytokeratin-positive cells from bone marrow of breast cancer patients between unstained cytokeratin-negative bone marrow cells. The cells
shown in A–C were isolated from patients in stage M0 and displayed normal CGH profiles (A, A-201-1; B, A-213-1; C, A-202-1; for LOH data of these cells
see Figure 5), while the cell shown in D (C-111-2) is isolated from a patient in stage M1. Note its larger size in comparison with the cells in A–C, suggesting
a polyploid genome.
E and F: GFP-annexin V single-positive cell showing the same cell in the GFP filter (E) and in bright-field microscopy (F).
G–I: GFP-annexin V and propidium iodide (PI) double-positive cell. GFP staining is shown in G, PI is shown in H, and bright field is shown in I.
J: Round cellular morphology is lost soon after cells become PI positive. Note the pale, flattened PI-positive cell giving low contrast, as compared with the
round, PI-negative cells with high contrast (bright-field microscopy with open PI filter).
K and L: Amorphous, PI-positive cell at later stages of cell death in bright-field microscopy (K) and PI filter (L).
M: LOH of unstained, GFP-annexin V, and GFP-annexin V-PI double-positive cells. Error bars indicate 95% confidence interval.
N: The mode of apoptosis induction influences the rate of LOH. Error bars indicate 95% confidence interval.lated PI-positive cells after induction of apoptosis using camp-
tothecin (1.5 and 3 hr). Here, even in camptothecin-induced
apoptosis, no difference was observed for LOH of nonapop-
totic, coisolated cells (n = 12; mean 9% and 95% CI, 0%–19%)
and PI-positive SKBR3 (n = 5; mean 14%, 95% CI, 0%–30%)
or SW480 cells (n = 6; no loss observed).
Finally, we reasoned that isolation of apoptotic cells on the
basis of annexin V and PI double labeling might still be too
early to detect significant DNA degradation in apoptotic cells.
However, once cells were PI positive, disintegration of cellular
morphology occurred very rapidly. During microscopic inspec-
tion, the cells became shiny, pale, and amorphous (Figures 2J–CANCER CELL : SEPTEMBER 20052L)—clearly different from the cytokeratin-positive cells that we
isolated from bone marrow of cancer patients (Figures 2A–2D).
We were unable to amplify DNA from cells with amorphous
appearance, indicating rapid DNA degradation once this stage
is reached. Taken together, these experiments rule out the pos-
sibility that apoptosis accounts for the high frequency of LOH
observed in CK-positive cells from bone marrow.
Identification of genomic regions frequently
affected by LOH
We then compared the frequency of LOH for control group 2
cells and cytokeratin-positive cells from groups A, B, and C231
A R T I C L Efor each marker using Fisher’s exact test. While we found no
characteristic differences between cells from control group 1
and 2, specific markers were significantly more often deleted
even in cytokeratin-positive cells without chromosomal abnor-
malities (group A) than in control group 2 cells (Table 1). These
markers may thus enable identification of DNA changes that
occur in cytokeratin-positive cells before the onset of chromo-
somal instability. The number of significantly altered markers
was similar for group A and group B cells and increased for
cells from group C, which often harbored chromosomal aberr-
ations within the tested regions. Since the markers spanned
relatively large genomic regions, this analysis provided only an
overview of where frequent LOH may occur. However, in two
of the five selected chromosomal regions, the markers with
highest statistical significance for LOH in cells from group A
mapped within genes functionally involved in adhesion and
cellular differentiation, i.e., CTNNB1 and APC (Table 1). On
chromosome 17, the gene encoding plakoglobin (JUP; posi-
tioned at 37.2 Mbp) was clearly not affected by LOH in cytoker-
atin-positive cells without CGH abnormalities, since the mark-
ers with highest significance mapped 7–8 Mbp apart. The
region of α-catenin (CTNNA1; positioned at 138.1 Mbp on
chromosome 5 between D5S500 and D5S1360) was not af-
fected in group A cells but may occasionally be deleted in
groups B and C. On chromosome 16, the marker most fre-
quently deleted in cells from group A (D16S485) mapped only
3 Mbp from the E-cadherin gene (CDH1; positioned at 67.3
Mbp) toward the telomere. While D16S3095 is more closely
located to CDH1, it was rarely informative in control cells and
may have reduced the statistical significance.
Therefore, we attempted to better define the regions harbor-
ing LOH and to validate the findings. We selected the two
markers displaying the highest statistical significance of LOH
in cells from group A (D16S485 and β-catenin marker) and
added eight markers for intragenic single-nucleotide polymor-
phisms (SNP) mapping proximally and distally to the microsat-
ellite marker D16S485 and 11 SNPs in distal or proximal loca-
tion of the β-catenin marker on chromosome 3. For these
markers, we tested all cells from group A. Since the samples
were not as often informative for the SNP markers as for the
microsatellite markers, we used a sliding window approach of
three adjacent markers for statistical evaluation of the regions.
Thus, the region on chromosome 16 (from 67.3 Mbp to 71.9
Mbp) was analyzed by nine windows, which covered 0.9 Mbp
on average. The larger region on chromosome 3 (33.4–44.6
Mbp) was analyzed by 12 windows covering 1.7 Mbp on
average. For all triplet markers, the rate of LOH was signifi-
cantly higher than that in control cells (Figure 3). Thus, the re-
gions comprising CDH1 (E-cadherin) and CTNNB1 (β-catenin)
are frequently lost in cytokeratin-positive cells without CGH ab-
normalities, strongly supporting the origin of the cells from
transformed breast tissue.
Comparison with the matched primary tumor
The SNP microsatellite analysis allowed the definition of re-
gions of frequent allelic losses in single disseminated breast
cancer cells. We then asked whether we could detect the same
LOH in the corresponding primary tumors. To this end, we ob-
tained tissue blocks of formalin-fixed, paraffin-embedded tu-
mors from 16 patients of group A. We performed laser micro-
dissection to isolate the tumor cells (Figures 4A and 4B), and232whenever possible (n = 8) we isolated DNA from several re-
gions of the primary tumors. Since archived laser-microdis-
sected, formalin-fixed, paraffin-embedded tissue frequently
contains degraded or damaged DNA, we used conditions that
we had previously defined for successful analysis (Stoecklein
et al., 2002). Sufficient material was isolated and globally am-
plified similarly to single cells, and only those markers mapped
on MseI fragments smaller than 400 bp were selected for
analysis (Stoecklein et al., 2002). Single disseminated cancer
cells and their matched primary tumors were compared for
allelic losses of 25 polymorphic markers. In general, the com-
parison revealed various scenarios, i.e., that all areas from a
primary tumor share the same genetic lesion with the dissemi-
nated cell, that only one or few areas from a primary tumor
match the disseminated cell(s), or that only one of several
disseminated cells matches an area of a primary tumor (Figures
4C and 4D). However, in 9/16 cases we could detect at least
one area within the matched primary tumor that shared at least
one LOH with the disseminated cell (Figure 4D).
Classifying a cytokeratin-positive cell as a tumor cell
Our analyses provided substantial evidence that the group of
cytokeratin-positive cells differs from the group of control cells.
Comparisons with primary tumors revealed a common genetic
change for some cells, most likely reflecting a shared descent.
However, the absence of such a shared change does not ex-
clude the possibility that the particular cell is indeed a tumor
cell. We therefore attempted to define criteria by which an indi-
vidual cytokeratin-positive cell with a normal CGH profile can
be identified as a tumor cell and constructed a classifier that
was trained to differentiate between group 2 control cells and
group A cells. Best classification was obtained with two mark-
ers only, D16S485 and the microsatellite marker that maps
within the β-catenin gene (β-catenin marker in Table S2 [primer
sequences]). Control cells from group 2 could be separated
from group A cells with an accuracy of 74% (the 95% CI being
64%–84%; Figure 5). Generally, this classifier can be used to
select breast tumor cells or control cells on the basis of LOH
markers. We tested this approach and were able to correctly
identify control cells from group 1 and tumor cells from group
B/C cells with a high specificity (88% control group 1, 90%
group B/C).
Identification of a subgroup of breast cancer patients
with early HER2 amplification
Since analysis of cells from group A appeared to uncover very
early genetic events in disseminated breast cancer, we asked
when the therapeutically important amplification of the HER2
gene takes place during genomic progression. We found that
HER2 gene amplifications emerge relatively late in cellular evo-
lution in most cases, although a subset of cytokeratin-positive,
CGH-normal cells displayed HER2 gene amplifications. To
study HER2 gene amplifications at 17q12, which are observed
in 25%–30% of primary breast cancers (Slamon et al., 1989),
we designed a quantitative (q) PCR approach and tested 92 of
the cytokeratin-positive cells previously analyzed for LOH and
CGH (Figures 6 and 7). Gain of HER2 was assigned to a cyto-
keratin-positive cell when the qPCR result differed significantly
from that obtained from control cells (Figures 6 and 7). Since
gene amplifications are defined as an increased ratio between
HER2 sequences and centromere copy number of chromo-CANCER CELL : SEPTEMBER 2005
A R T I C L EFigure 3. High-resolution analysis of markers in the proximity of CTNNB1 on chromosome 3 and D16S485 on chromosome 16
The table depicts markers, their chromosomal location (in Mbp), and the p values (corrected for multiple testing by a FDR approach) for a region covered
by three consecutive markers. Each p value is written next to the marker in the center of a triplet. Red and blue dots indicate LOH per cell for each marker
triplet of cells from group A and cells from the controls, respectively. Scale on x axis is in Mbp. “beta” stands for “β-catenin marker” (see Table 1).value for the HER2 PCR in a karyotypically normal cell by defi-
Figure 4. Comparison of disseminated tumor cells and matched primary tumors
A: Hematoxylin-eosin staining of primary breast cancer with considerable stromal component and infiltrating cells.
B: Hematoxylin staining of consecutive tissue section for laser microdissection at higher magnification. A green line marks the area selected for microdissec-
tion. Several such areas within a region were collected and pooled. Several pools were prepared from various regions of primary tumors.
C: Examples of LOH analysis. In case 204, loss of D16S485 was observed only in the tumor cells (upper panel), while PT1 and the disseminated cancer cell
share loss of the same allele of rs1565957 (lower panel). D16S485 is lost in all samples of the primary tumor (PT1-PT6) and in the disseminated cancer cell of
case 227. In case 203, all disseminated cancer cells display loss of rs740178, while the primary tumor harbors both alleles. (The upper weak band in cell #2
represents an incomplete restriction digest).
D: Overview of LOH analysis of group A cells and their matched primary tumors. Green color indicates informative markers, red indicates heterozygous
loss, and blue indicates homozygous loss. “beta” stands for “β-catenin marker” (see Table 1).
from metastatic patients (Figure 7B). Thus, the frequency ofsome 17, they can be assigned to cells with significantly ele-
vated HER2measurements when the centromere copy number
of chromosome 17 is normal. Consequently, an increasedCANCER CELL : SEPTEMBER 2005nition identifies a HER2 gene amplification. We found HER2
amplification or gain in 9/52 (17%) cases (group A 6/37 [16%]
and group B 3/15 [20%]) in stage M0 and in 22/40 (55%) cells233
A R T I C L EFigure 5. Classification of cells from group A
based on the markers β-catenin and D16S485
A classifier was trained to distinguish between
control cells and cytokeratin-positive cells with-
out CGH aberrations. All markers (shown at the
bottom of the figure) are ordered according to
their chromosomal location on chromosomes 3,
5, 16, and 17. Cell identifiers are given on the
right side (with letter A indicating cells from
group A and letter K indicating control group 2
cells). Cells are ordered according to their prob-
ability of being classified as cells from group A.
Green color indicates informative markers, red
indicates heterozygous loss, and blue indicates
homozygous loss.cytokeratin-positive cells with HER2 amplification increased
significantly during systemic progression (p < 0.001 for group
A compared with group C; Figures 7B and 7C). Cells from
groups A and B did not differ significantly with regard to HER2
amplification. Since we had previously noted that clinical me-
tastasis concurs with the emergence of chromosomal breaks
throughout the genome (Schmidt-Kittler et al., 2003) of cyto-
keratin-positive cells, we tested whether HER2 gains are asso-
ciated with chromosomal breaks as well. Indeed, in the major-
ity of breast cancers HER2 is gained after the onset of large
genomic rearrangements in disseminated tumor cells (Figure
7D). When we analyzed the frequency of HER2 gains in pa-
tients from whom we had detected and isolated more than one
cell, we found HER2 amplified in all isolated cells (“homogen-234eous gain” in Figure 7E) in 1/9 (11%) M0 patients. During dis-
ease progression, the percentage of mixed populations
(“heterogeneous gain”) and cell populations with homogen-
eous HER2 gain increased (Figure 7E). We also compared the
reports of HER2 immunohistochemistry of the matched pri-
mary tumors with the qPCR results of single disseminated can-
cer cells. Reports were available for 27 primary tumors, and
HER2 amplification was assumed for strong staining (3+). Con-
cordant amplifications of primary tumors and disseminated tu-
mor cells were found in 1/27 cases, while HER2 was amplified
in primary tumors but not in the disseminated cells in 10/27
matched pairs, and in 5/27 cases only the disseminated cells
displayed a HER2 amplification. The remaining pairs were
double negative. Thus, these data suggest that HER2 amplifi-CANCER CELL : SEPTEMBER 2005
A R T I C L EFigure 6. Analysis of HER2 amplification and karyotypic abnormalities
CGH profiles of three single cells selected from M0 stage patients with CGH
abnormalities (sample B-026-1) and without CGH abnormalities (sample
A-012-4) and M1 stage patients (sample C-114) and statistical evaluation
of qPCR of HER2 versus control primers for the respective cell (mean rank
test) and the control cells (mean rank control). Asterisks in the CGH profiles
indicate the location of the HER2 primers on chromosome 17 and the con-CANCER CELL : SEPTEMBER 2005might contribute to the onset of disease. Although such events
trol primers on chromosomes 3 and 7. Red and green dashed lines indicate
thresholds of significance for chromosomal losses and gains, respectively,
and likewise, red and green bars next to the chromosome ideogram mark
regions of loss and gain. p value indicates whether or not values of mean
rank test and mean rank control differed significantly (here significant for
samples A-012-0 and C-114).cation is a very early mutational event only in a subset of pa-
tients, while in most cases its gain occurs late in local and
systemic tumor progression. Tumor cells with HER2 amplifica-
tion apparently become selected during systemic disease pro-
gression.
Discussion
We describe here the finding of a cell population in bone mar-
row of breast cancer patients that is characterized by the ex-
pression of epithelial cytokeratins and lack of chromosomal
abnormalities, but general genetic instability and subchromo-
somal DNA changes. Due to their characteristics, the cells may
represent examples of the early stages of metastasis and thus
could be used to identify early genetic changes in breast
cancer.
We could exclude the possibility that apoptosis accounts for
these findings. While camptothecin-induced apoptosis re-
sulted in marginally increased LOH, serum starvation did not.
Genomic DNA could be globally amplified from single cells un-
dergoing apoptosis as long as their cellular appearance was
not obviously destroyed. Regardless of how apoptosis was in-
duced, cytokeratin-positive cells with normal CGH profiles
from bone marrow displayed a significantly higher rate of LOH
than apoptotic cells. Since only morphologically intact cytoker-
atin-positive cells were isolated for this study, and their DNA
had previously been successfully used in CGH analysis, and
since none of the patients in stage M0 underwent chemother-
apy prior to bone marrow sampling, the LOH of cytokeratin-
positive cells apparently reflects their biology.
The regions frequently affected by significant LOH included
genes with a potential role in the regulation of adhesion and
differentiation, encoding E-cadherin, β-catenin, and APC. Al-
though the functional consequences of LOH of these genes for
tumor promotion and systemic progression are largely un-
known, there is increasing evidence that a reduction in gene
dosage by loss of one allele (haploinsufficiency) may severely
compromise genome function (Kaern et al., 2005). For exam-
ple, in a mouse model of combined APC and E-cadherin muta-
tion haploinsufficiency of E-cadherin resulted in an increased
number of tumors (Smits et al., 2000). For many tumor sup-
pressor genes, the importance of reduced gene dosage is
being recognized as a contributing mechanism of tumor pro-
gression (Santarosa and Ashworth, 2004). Generally, haploin-
sufficiency has been linked to increased stochasticity of gene
expression. Stochastic simulations of a model of gene expres-
sion have shown that diploid cells have a higher probability
than haploid cells of maintaining the abundance of an ex-
pressed gene product above a low threshold value (Cook et
al., 1998). It was concluded that loss of one allele reducing
expression of an essential factor below a crucial threshold235
A R T I C L EFigure 7. Quantitative PCR analysis of the HER2 gene in single disseminated cancer cells isolated from patients with and without metastasis
A: Amplification of HER2 (top) and the reference gene OPN1SW of two cytokeratin-positive cells with (solid line) and without (thin dashed line) HER2
amplification. Note the ratios of the crossing points for HER2/OPN1SW (20/26.5 versus 28/27.6), indicating a higher HER2 copy number for the first sample.
B: Percentage of HER2 gains and HER2 amplification and deletion in cells from groups A–C. In only one cell from group B, the higher values for the HER2
amplicons originated from an additional chromosome 17.
C: Analysis of HER2 amplification and deletion based on patients (i.e., from some patients several cells were isolated; in percent).
D: Percentage of HER2 amplification and deletion in cells with or without genomic rearrangements.
E: Distribution of patients from whom more than a single cell was isolated with or without HER2 amplification (in percent). Note that during disease
progression the number of patients increases that have a mixed population of disseminated tumor cells (heterogeneous amplification) and that harbor a
homogeneous cell population with respect to HER2 amplification.
Groups A–C were defined by clinical stage (groups A and B, M0; group C, M1) and CGH profile (group A, normal profile; groups B and C, aberrant profile).would occur only rarely, the probability would gradually accu-
mulate, making the onset of disease more likely later in the life
of the organism (Kaern et al., 2005).
In this context, our findings suggest a model in which spo-
radic cancers may result from genome-wide double-strand
breaks, subchromosomal DNA losses, and resulting increased
stochasticity of gene expression in individual cells, which are
then subject to natural selection. So far, mutations in specific
genes (Hahn et al., 1999; Hanahan and Weinberg, 2000), aneu-
ploidy (Duesberg et al., 2004; Li et al., 2000), and telomere
shortening leading to genomic rearrangements (Artandi et al.,
2000; DePinho, 2000) have been implicated in initiating local
and systemic malignant disease. We delineated the genomic
aberrations in human breast cancer by multiple genetic analy-
ses (i.e., CGH, LOH, and qPCR) of single disseminated cancer
cells and determined the sequence of genomic changes. Rela-
tive to a starting point of a normal diploid genome and an end
point that is represented by a metastatic cancer cell (charac-
terized by CGH-defined genomic rearrangements such as in-
trachromosomal gains or losses or DNA breaks that include
the telomeres [Schmidt-Kittler et al., 2003]), cytokeratin-posi-
tive cells without CGH abnormalities are located close to the
starting point. They differ from normal cells by subchromoso-
mal DNA losses and in some cases gene amplifications, such
as HER2 gains. The next genomic change could be the emer-
gence of aneuploidy and later on large CGH-defined chromo-
somal rearrangements (Schmidt-Kittler et al., 2003).
Such a model is consistent with two recent reports indicating
that replication stress in precancerous lesions leads to double-
strand breaks not detected by CGH and activates the DNA236damage checkpoint (Bartkova et al., 2005; Gorgoulis et al.,
2005). Replication stress was very prominent at the stage of
hyperplasia, and chromosomal aberrations arose only after the
breakdown of the DNA damage checkpoint. In light of the fact
that 95% of primary tumors and preinvasive stages of mam-
mary neoplasias display chromosomal changes detectable by
CGH, cytokeratin-positive tumor cells without CGH aberrations
must be representatives of a very early stage of genomic pro-
gression and possibly disseminated at the stage of hyperpla-
sia. Therefore, the finding that at the time point of surgery more
than 50% of disseminated breast cancer cells display normal
karyotypes (Schmidt-Kittler et al., 2003) remains puzzling and
is at variance with the linear progression model deduced from
colorectal cancer. It could indicate the existence of a particular
state of cellular transformation at which the cells are prone to
disseminate, whereas late, chromosomally aberrant primary tu-
mors seed fewer cells—at least relative to the total number of
cells in the primary tumor. It also suggests that the dissemi-
nated cells will have to overcome several thresholds to full ma-
lignancy, first the DNA damage checkpoint and second telo-
mere crisis. The need to overcome these thresholds might
explain the relatively long latency periods (on average 6 years)
for small breast cancers until metastases become apparent
and suggests that the probability to grow into metastasis is
small for an individual disseminated tumor cell.
Although detection of cytokeratin-positive cells in bone mar-
row is relevant for prognosis (Braun et al., 2000b; Gebauer et
al., 2001; Gerber et al., 2001; Wiedswang et al., 2003) and pre-
diction of therapy response (Braun et al., 2000a; Janni et al.,
2005), these studies did not differentiate between CK-positiveCANCER CELL : SEPTEMBER 2005
A R T I C L Ecells with and without abnormal CGH profiles. Survival analysis
of our cohort within the next years should provide helpful infor-
mation. However, irrespective of whether disseminated tumor
cells with normal karyotypes will eventually form metastases,
they might be interesting for therapy target research—not nec-
essarily as target cells themselves but as tools to define rele-
vant target genes. Early dissemination and independent pro-
gression at ectopic sites is likely to result in malignant genotypes
and phenotypes that differ not only between disseminated cells
and their primary tumors but also between colonies residing at
different ectopic sites. Thus, the DNA changes that are the best
candidates for being shared among all tumor cells are those
preceding or causing dissemination. This rationale is exempli-
fied by the finding that early amplification of HER2, i.e., prior
to large CGH-defined genomic rearrangements, defines a par-
ticular group of M0 stage breast cancer patients. In most
cases, HER2 amplification will occur late in cancer progression
and may not be present in disseminated cancer cells when
adjuvant treatment is applied after surgery. Therefore, patients
with early HER2 amplification might benefit more from adjuvant
therapy with HER2-directed drugs than those that amplify the
gene later in disease progression.
For all other patients, similar targets are yet to be defined.
Comparison between primary tumors and disseminated cancer
cells identified a common deletion in 50% of analyzed cases.
While this supports the origin of the cells from the primary site,
it also indicates that more work is necessary to identify
changes that caused the growth of sporadic cancers. There-
fore, a genome-wide, comparative survey of disseminated cy-
tokeratin-positive cells and primary tumors might be helpful for
the identification of genetic lesions that initiate sporadic cancer
and metastatic spread and useful for the detection of novel
therapy targets.
Experimental procedures
Cell isolation and template preparation
Cytokeratin-positive cells of patients were isolated, and their DNA was am-
plified and used for CGH as described (Klein et al., 1999, 2002). Samples
were taken from the study cohort published (Schmidt-Kittler et al., 2003).
Informed consent was obtained from all patients, and the local ethics com-
mittees in Frankfurt and Augsburg approved the study. For LOH analysis,
the primary PCR products were reamplified for all samples using 0.5 l as
template. Reamplification from primary PCR products was performed in 50
l containing 5 l Expand Long Template Puffer 1 (Roche), 5 l LIB 1 or
Mse 21 primer (10 M), 1.75 l dNTP (10 mM), 1.25 l BSA (Roche), and
0.5 l Taq-Polymerase (5 U/l; Roche) for 30 cycles. No substantial differ-
ences in the amplification efficiency of single-copy sequences were ob-
served between primary PCR products and reamplified PCR products. The
positive control for each patient was generated by incubating the slide from
which single cytokeratin-positive cells had been isolated with 80 l of solu-
tion A (100 mM KCl, 10 mM Tris/HCl [pH 8.3], 2.5 mM MgCl2) and 80 l
solution B (10 mM Tris/HCl [pH 8.3], 2.5 mM MgCl2, 1% Tween 20, 1%
NP40, Proteinase K 120 g/ml) for 10 hr at 42°C, followed by inactivation
of Proteinase K at 80°C for 10 min. After precipitation, the DNA was globally
amplified like the DNA of the single cells.
LOH analysis
A volume of 0.5 l of reamplified primary PCR product was used as tem-
plate for sequence-specific PCR. The primer sequences for the microsatel-
lite and the PCR-RFLP markers are provided as Supplemental Data. Se-
quence-specific PCR using the microsatellite or PCR-RFLP markers was
performed in a volume of 10 l containing 1 l 10× PCR buffer (10 mM
MgCl2, 100 mM Tris [pH 8.5], 500 mM KCl, 1 mM dNTPs), 0.5 l forward
primer (8 M), 0.5 l reverse primer (8 M), 0.25 l BSA (Roche), 0.1 lCANCER CELL : SEPTEMBER 2005Taq-Polymerase (5 U/l; Roche). Microsatellite markers were run on a verti-
cal, 7% polyacrylamide gel. The DNA was visualized by incubating the gel
for 10 min with SYBR Green (1× TBE, SYBR Green 1:10,000) and analyzed
on a fluorimager. Detailed information about the restriction digest of SNP
markers can be obtained upon request.
Quantitative PCR
Real-time PCR was performed using a LightCycler (Roche, Mannheim, Ger-
many) and Fast Start Master SYBR Green Kits (Roche) using 1 l of primary
PCR products from the whole genome amplification diluted 1:20 in H2O.
Analysis was done using the RelQuant software (Roche) with PCR efficiency
normalization and a reference sample included for every run. Three primers
within the HER2 locus were selected, and three primers on two chromo-
somes (chromosome 3 and chromosome 7) served as loading control. Mea-
surements showing unspecific products in the melting curve analysis or
CGH aberrations on the control loci were discarded from further statistics.
All relative expression ratios HER2/reference from duplicate measurements
were compared to those from 55 normal diploid cells (from control groups
1 and 2). Samples showing significant difference (p < 0.05) from the diploid
cells in a Mann-Whitney test were classified as either “amplified” or “de-
leted” for HER2 depending on their mean rank value. Primer sequences are
provided in Table S2.
Cell culture of mammary epithelial cells and apoptosis assay
Normal breast tissue after reduction mammoplasty was dissociated to sin-
gle cells by mechanical and collagenase/hyaluronidase dissociation as de-
scribed (Stingl et al., 1998). Single cells were cultivated in serum-free me-
dium conditioned with B27, 20 ng/ml EGF, and 20 ng/ml bFGF under
nonadhering conditions (Dontu et al., 2003).
After 7 days of culture, mammospheres of 50–150 m diameter had
grown out and were harvested by centrifugation at 38 × g and disintegrated
by consecutive cycles of incubation with trypsin/EDTA and mechanical
dissociation. The single-cell suspension was plated onto collagen-coated
eight-well chamber slides in differentiation medium complemented with 5%
serum and 10 ng/ml EGF. After 2–3 days of incubation, growth medium was
removed and replaced by either normal growth medium as positive control,
serum-free medium, or medium containing 2 g/ml camptothecin. Apopto-
sis was detected after trypsination using 5 g/ml PI and GFP-annexin V
(1:500) in annexin binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM
CaCl2) for 15 min (Egger et al., 2003).
Statistical analysis
The rate of LOH of all subgroups was compared using a two-sided exact
Wilcoxon signed rank test in the software package R. To exclude a patient
effect, a simulation study by randomly choosing one cell per patient was
performed. All markers were compared using Fisher’s exact test. Noninfor-
mative cells and homozygous losses were treated as missing values. The
false discovery rate (FDR)-controlling procedure by Benjamini and Hoch-
berg was used to account for multiple testing. Adjacent markers were com-
bined in a sliding window to enhance the reliability in the result. All measure-
ments of three adjacent markers were merged and compared by Fisher’s
exact test.
Machine learning
The decision tree algorithm C5.0 was applied as classifier using a 10-fold
crossvalidation (CV) and a balanced design. The classification accuracy
was estimated from 10 runs (10 × 10 CV). Noninformative markers and
homozygous losses were encoded as missing values. All calculations were
performed with the software package Clementine (http://www.spss.com/
clementine/), version 8.5. The standard errors for the accuracy values and
the classification probabilities were calculated as described by SPSS. For
the control group 1, group C, and group B cells, the specificity was esti-
mated from class assignments with a classification probability >60%.
Supplemental data
The Supplemental Data include two tables and one figure and can be found
with this article online at http://www.cancercell.org/cgi/content/full/8/3/227/
DC1/.237
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